drugset
drugset / Trial / NCT00231634

A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy

NCT00231634 ↗

Phase 3 Terminated 31 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the effectiveness and safety of topiramate with placebo in the treatment of obesity and Type 2 diabetes mellitus in patients who have failed on sulfonylurea therapy.

Timeline

Start
2001-05
Primary completion
—
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 96 mg Oral
Subject Topiramate Small molecule 192 mg Oral
Subject Topiramate Small molecule 256 mg Oral

Indications

obesity disorder type 2 diabetes mellitus